| Literature DB >> 32244468 |
Navaneethaiyer Umasuthan1, Xi Xue1, Albert Caballero-Solares1, Surendra Kumar1, Jillian D Westcott2, Zhiyu Chen2, Mark D Fast3, Stanko Skugor4, Barbara F Nowak5, Richard G Taylor6, Matthew L Rise1.
Abstract
Parasitic sea lice (e.g., Lepeophtheirus salmonis) cause costly outbreaks in salmon farming. Molecular insights into parasite-induced host responses will provide the basis for improved management strategies. We investigated the early transcriptomic responses in pelvic fins of Atlantic salmon parasitized with chalimus I stage sea lice. Fin samples collected from non-infected (i.e. pre-infected) control (PRE) and at chalimus-attachment sites (ATT) and adjacent to chalimus-attachment sites (ADJ) from infected fish were used in profiling global gene expression using 44 K microarrays. We identified 6568 differentially expressed probes (DEPs, FDR < 5%) that included 1928 shared DEPs between ATT and ADJ compared to PRE. The ATT versus ADJ comparison revealed 90 DEPs, all of which were upregulated in ATT samples. Gene ontology/pathway term network analyses revealed profound changes in physiological processes, including extracellular matrix (ECM) degradation, tissue repair/remodeling and wound healing, immunity and defense, chemotaxis and signaling, antiviral response, and redox homeostasis in infected fins. The QPCR analysis of 37 microarray-identified transcripts representing these functional themes served to confirm the microarray results with a significant positive correlation (p < 0.0001). Most immune/defense-relevant transcripts were downregulated in both ATT and ADJ sites compared to PRE, suggesting that chalimus exerts immunosuppressive effects in the salmon's fins. The comparison between ATT and ADJ sites demonstrated the upregulation of a suite of immune-relevant transcripts, evidencing the salmon's attempt to mount an anti-lice response. We hypothesize that an imbalance between immunomodulation caused by chalimus during the early phase of infection and weak defense response manifested by Atlantic salmon makes it a susceptible host for L. salmonis.Entities:
Keywords: 44K microarray; Lepeophtheirus salmonis; Salmo salar; anti-sea lice response; chalimus; fin transcriptome; immunogenomics; immunomodulation
Mesh:
Year: 2020 PMID: 32244468 PMCID: PMC7177938 DOI: 10.3390/ijms21072417
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Overview of resulting global transcript expression profiles. (A) The global profile of differentially expressed probes (DEPs) identified by the Significance Analysis of Microarrays (SAM) algorithm using a modified t-test. Grey and black color bars (and the numbers on them) indicate the number of DEPs at false discovery rates (FDRs) of 5% and 1%, respectively. (B) Venn diagram showing the distribution of 6568 DEPs among three different comparisons of lice infection treatments. Numbers in red (↑) and green (↓) indicate up- and down-regulated DEPs, respectively. FC ≥ # indicates the number of DEPs with a fold-change value ≥ |2|. Detailed profiles of DEPs are available in Supplementary Files S1 and S2. (C,D) Principal coordinate analysis (PCoA) and hierarchical clustering analysis of fin samples from control (PRE) and sea lice-infected (ADJ and ATT) fish based on the expression dataset of DEPs (n = 6568). (C) PCoA of a resemblance matrix generated using Bray-Curtis similarity coefficients. (D) Complete linkage clustering was performed using Pearson correlation in the PRIMER 6.1.15 package. vs., versus.
Figure 2Venn diagram showing differentially expressed probes (DEPs) and/or genes (DEGs) among different segments considered in the Results and Discussion Sections. Each segment is assigned with a number (1–4). Bold numbers indicate the DEPs contributing to a particular segment. The number of DEGs corresponding to DEPs of each segment is shown. FC_# indicates the number of DEPs with a fold-change ≥ |2|. It should be noted that DEPs in segment 1 required to comply with the criteria of FC ≥ |2| in both comparisons ADJ versus PRE and ATT versus PRE. Only the features with FC ≥ |2| were subjected to Blast2GO enrichment analyses, except for segment 2 as this probe list was relatively shorter. Whereas, all the DEGs of each segment were used in gene ontology (GO)/pathway terms analyses using ClueGO. vs., versus.
Figure 3Summary of GO terms annotation for all DEPs responsive to sea lice infection and their enrichment analyses. Three different categories of GO terms are illustrated: (A) biological process (BP), (B) molecular function (MF), and (C) cellular component (CC). Non-redundant probes constituted from the union of probes with fold-change ≥ |2|from ADJ versus PRE and ATT versus PRE lists, and all DEPs from ATT vs. ADJ list (Figure 1B; Supplementary File S3; n = 1014 DEPs) were annotated using the Blast2GO package. Charts represent the distribution of GO terms, in which BP, MF, and CC are shown at GO levels 2, 3, and 2, respectively. Enrichment analyses were performed using the entire 44K array as reference (Fisher’s Exact Test, FDR < 0.01). Significantly enriched GO terms are boxed and color-filled. Complete lists of over-/under-represented GO terms and their statistics are available in Supplementary File S3.
Figure 4Gene-Ontology (GO) term enrichment and pathway term network analysis of DEGs shared by ADJ versus PRE and ATT versus PRE lists (1928 DEPs). (A) Upregulated DEGs (651 DEPs). (B) Downregulated DEGs (1277 DEPs). GO enrichment analysis was performed by the ClueGO [32] plugin in Cytoscape [33]. Two databases were used, including GO (BP, MF, and CC) and Reactome pathways for retrieving associated terms. Only the networks and pathways with p < 0.05 are illustrated. Functionally grouped networks with terms as nodes linked by edges based on their kappa score level (≥0.4) are shown. Related-GO terms are grouped and illustrated with distinct color and labeled with the same color. The node size represents the significance of term enrichment. Functionally related groups partially overlap. When a particular GO term is shared by two or more different GO cluster groups, the node is shown by multiple colors. The shape of the nodes indicates the source of the database from where a term was retrieved (ellipse, GO_BP; rectangle, GO_MF; triangle, GO_CC; Reactome, hexagon). The thickness of edges indicates the kappa score (strength of intra-connectivity between cluster groups). Related clusters are shown together within a dotted border and labeled with broad themes for discussion purposes. Refer to the Supplementary Files S7 and S8 for details and high-resolution images.
Figure 5Gene-Ontology (GO) term enrichment and pathway term network analysis of DEGs in ATT versus ADJ list (90 DEPs). Refer to the caption of Figure 4 and Supplementary File S9 for additional details and the high-resolution image.
Figure 6Heatmap illustration and hierarchical clustering analyses of DEPs between ATT and ADJ sites in Atlantic salmon fins across treatment groups. Clustering and heatmap results as an illustration of high-resolution figures are available in Supplementary Figure S6. Rows and columns represent the log2 fold-change values of different transcript expression levels (90 DEPs) and individual fish from the lice-infection groups (colored boxes), respectively. Genes were median-centered and clustered using Pearson correlation and complete linkage hierarchical clustering. The colored boxes below the top legend represent individual fish from the lice-infection groups. *, transcripts that were QPCR-assayed.
Selected transcripts playing roles in different physiological processes (except those functioning primarily in immunity) and their fold-change values from SAM.
| Category | Probe ID (44K) 1 | Gene Symbol_v1 2 | Gene Description 3 | Fold-Changes 4 | Segment 5 | ||
|---|---|---|---|---|---|---|---|
| ADJ versus PRE | ATT versus PRE | ATT versus ADJ | ( | ||||
|
| C090R002 |
| Homeobox protein Hox-D12a-like | −13.7 | −14.3 | NS | 1 |
| C180R160 |
| Homeobox protein Hox-D10 | −3.1 | −2.8 | NS | 1 | |
| C072R152 |
| Homeobox protein Hox-A9b-like | −2.6 | −2.0 | NS | 1 | |
| C191R067 |
| Homeobox protein Hox-A11a-like | −2.2 | −2.2 | NS | 1 | |
| C072R1164 |
| Homeobox protein Hox-C9 | 2.9 | 2.6 | NS | 1 | |
| C032R060 |
| Homeobox protein Hox-A5 | 3.1 | 2.7 | NS | 1 | |
| C033R115 |
| Homeobox protein Hox-C6-like | 3.1 | 3.0 | NS | 1 | |
| C190R1622 |
| CCAAT/enhancer-binding protein beta (C/EBP beta) | NS | NS | 2.0 | 2 | |
| C262R105 |
| Zinc finger protein Gfi−1b | 7.0 | 22.4 | NS | 1 | |
| C088R057 |
| Peroxisome proliferator activated receptor delta | NS | 29.9 | 8.7 | 2 | |
|
| C149R1704 |
| Cytochrome c oxidase subunit 6B1 | −3.8 | −3.0 | NS | 1 |
| C201R1002 |
| Transketolase | 2.3 | 1.9 | NS | 1 | |
| C255R056 |
| Glucose-6-phosphatase | 1.3 | 2.2 | 1.6 | 1 | |
| C228R118 |
| Fructose-bisphosphate aldolase C | 4.3 | 8.2 | NS | 1 | |
| C120R022 |
| NADH dehydrogenase subunit 1 | 2.9 | 3.1 | NS | 1 | |
| C150R058 |
| Methyltransferase-like protein 17 | 3.9 | 9.4 | NS | 1 | |
| C138R1213 |
| Glyceraldehyde-3-phosphate dehydrogenase | 2.5 | 2.9 | NS | 1 | |
| C217R012 |
| Arachidonate Lipoxygenase 3 (Hydroperoxide isomerase) | 5.9 | 16.7 | NS | 1 | |
|
| C178R076 |
| L-dopachrome tautomerase-like | −20.9 | −18.2 | NS | 1 |
| C218R159 |
| 5,6-dihydroxyindole-2-carboxylic acid oxidase | −11.8 | −13.1 | NS | 1 | |
| C217R115 |
| Tyrosinase | −9.9 | −11.2 | NS | 1 | |
|
| C184R0187 |
| Collagen alpha-1(X) chain | −4.2 | −4.1 | NS | 1 |
| C199R006 |
| Collagen alpha-1(VI) chain | −2.8 | −2.6 | NS | 1 | |
|
| C114R0492 |
| Collagen alpha-1(XV) chain | −2.2 | −2.2 | NS | 1 |
|
| C095R156 |
| Laminin subunit gamma-1 | −3.9 | NS | NS | 3 |
| C184R0302 |
| Fibronectin | −3.7 | −1.8 | 2.0 | 1,2 | |
| C170R165 |
| Biglycan paralog a | −2.5 | −2.6 | NS | 1 | |
| C237R076 |
| Biglycan paralog b | −4.6 | −3.6 | NS | 1 | |
| C222R057 |
| Decorin | −1.8 | −2.4 | NS | 1 | |
| C265R1342 |
| Serine protease HTRA1 | −2.2 | −2.1 | NS | 1 | |
| C240R103 |
| Serine protease HTRA3 | −2.1 | −1.8 | NS | 1 | |
| C176R1514 |
| Cathepsin B | −2.0 | NS | NS | 3 | |
| C200R1378 |
| Annexin A13 | −2.4 | −2.4 | NS | 1 | |
| C143R1655 |
| Annexin A2 | −2.4 | NS | NS | 3 | |
| C185R0983 |
| 47 kDa HSP/collagen-binding protein | −2.3 | −2.2 | NS | 1 | |
| C015R046 |
| Integrin alpha-10 | −2.6 | NS | NS | 3 | |
| C080R0812 |
| Transforming growth factor-beta-induced protein | −2.0 | −1.9 | NS | 1 | |
| C205R1352 |
| Connective tissue growth factor (CCN family member 2) | −2.1 | NS | NS | 3 | |
| C098R103 |
| Fibroblast growth factor 1 | −11.8 | NS | 5.0 | 2 | |
| C081R049 |
| Matrix metalloproteinase-9 paralog a | −2.5 | NS | 2.2 | 2 | |
| C047R004 |
| Matrix metalloproteinase-9 paralog b | −2.2 | NS | NS | 3 | |
| C137R132 |
| Matrix metalloproteinase-13 (Collagenase 3) paralog d | −3.0 | −1.9 | NS | 1 | |
| C245R1523 |
| Matrix metalloproteinase-13 (Collagenase 3) paralog b | −5.2 | NS | 3.3 | 2 | |
| C133R147 |
| Matrix metalloproteinase-13 (Collagenase 3) paralog c | NS | NS | 2.9 | 2 | |
| C048R1628 |
| Matrix metalloproteinase-2 | −2.3 | −2.3 | NS | 1 | |
| C062R075 |
| Matrix metalloproteinase-19 | −3.2 | −2.1 | NS | 1 | |
| C099R050 |
| Matrix metalloproteinase-23b | −2.1 | −1.6 | NS | 1 | |
| C246R1563 |
| Metalloproteinase inhibitor 2 paralog b | −2.7 | NS | 1.9 | 2 | |
| C242R139 |
| Metalloproteinase inhibitor 2 paralog c | −2.4 | NS | NS | 3 | |
| C135R154 |
| Metalloproteinase inhibitor 3 | −3.9 | −2.5 | NS | 1, 3 | |
|
| C220R1344 |
| Hemoglobin subunit alpha (and -4) | −2.9 | −2.6 | NS | 1 |
| C171R16421 |
| Hemoglobin subunit beta | −3.2 | −3.0 | NS | 1 | |
| C088R0865 |
| 5-aminolevulinate synthase | −2.5 | −2.3 | NS | 1 | |
| C255R1032 |
| Cytoglobin-2 | 2.0 | NS | NS | 3 | |
|
| C104R146 |
| Thioredoxin domain-containing protein 5 | −2.4 | −1.8 | NS | 1 |
| C264R1092 |
| Redox-regulatory protein fam213a (peroxiredoxin-like 2A) | −6.4 | −6.7 | NS | 1 | |
| C174R1432 |
| Glutathione peroxidase 7 | −2.9 | −3.1 | NS | 1 | |
| C210R1264 |
| Glutathione S-transferase A-like | −2.6 | −2.1 | NS | 1 | |
| C115R1146 |
| Neutrophil cytosol factor 2-like isoform X2 | −1.9 | −1.6 | NS | 1 | |
| C211R1253 |
| Thioredoxin paralog b | −2.7 | NS | 2.2 | 2, 3 | |
| C115R1145 |
| Peroxiredoxin 1 paralog a | −1.7 | NS | NS | 3 | |
| C198R137 |
| Ferritin heavy chain | −1.6 | NS | NS | 3 | |
| C123R0752 |
| Ferritin, middle subunit | −2.7 | NS | NS | 3 | |
1 Identifier of the probe on the 44K array; if a transcript is represented by multiple probes, fold-change (FC) values are presented as mean FC values of all probes and the number of probes contributing to the mean FC is indicated by a subscript number next to the ID. 2 Official gene symbols (version 1) are based on multiple annotations and majority of them are represented in HGNC (https://www.genenames.org/) and/or GeneCard (https://www.genecards.org/) databases. *, transcripts that were QPCR-assayed. †, middle subunit of ferritin is not found in mammals and a putative symbol is used (alias ftm). 3 Name(s) or alias(es) obtained from annotation. Refer the Supplementary File S1 for additional details. 4 FC in three different comparisons for differentially expressed probes (DEPs; false discovery rate < 0.05) obtained from Significant Analysis of Microarray (SAM). Fold downregulation was calculated as the inverse of FC (i.e., -1/FC) for the original values that were less than one in the SAM output. If a probe is absent in a particular comparison, the corresponding FC is indicated by NS (not significant). ADJ versus PRE, ATT versus PRE, and ATT versus ADJ indicate the FC of first treatment group with respect to the second. Most of the DEGs presented here possess FC ≥ 2 and are biologically relevant to sea lice infection. 5 In which segment (refer to Figure 2) of the microarray DEP list a particular transcript is present.
Selected transcripts associated primarily with different components of the immune system and their fold-change values from SAM.
| Category | Probe ID (44K) 1 | Gene Symbol_v1 2 | Gene Description 3 | Fold-Changes 4 | Segment 5 | ||
|---|---|---|---|---|---|---|---|
| ADJ versus PRE | ATT versus PRE | ATT versus ADJ | ( | ||||
|
| C188R0745 |
| Complement component C1q receptor | −2.1 | −1.7 | NS | 1 |
|
| C084R1092 |
| CD209 antigen | −1.9 | −1.8 | NS | 1 |
| C126R092 |
| CD302 molecule | −2.1 | −2.0 | NS | 1, 4 | |
| C220R1582 |
| Mannose-binding protein C | −2.4 | −2.4 | NS | 1 | |
| C001R1353 |
| Macrophage mannose receptor 1 | −1.8 | NS | NS | 3 | |
| C117R009 |
| C-type lectin domain family 4 member M (CD209-like) | −2.0 | NS | NS | 3 | |
| C103R112 |
| C-type lectin domain family 4 member E | −2.1 | NS | 2.6 | 2, 1 | |
| C089R09910 |
| Galectin-1 | −2.9 | −3.2 | NS | 1 | |
|
| C180R124 |
| C-C motif chemokine 4 | −6.5 | −4.3 | NS | 1 |
|
| C203R129 |
| Transforming growth factor beta-3 | NS | −1.6 | NS | 4 |
| C185R1654 |
| Chemokine-like receptor 1 | −3.4 | −2.8 | NS | 1 | |
| C095R021 |
| C-C motif chemokine 17-like | −1.6 | NS | NS | 3 | |
| C111R068 |
| Interleukin-1 receptor type 2 | −2.4 | NS | NS | 3 | |
| C252R0962 |
| C-C chemokine receptor type 4 | −1.8 | NS | NS | 3 | |
| C159R1502 |
| Interleukin-13 receptor subunit alpha-2 | 3.1 | 3.0 | NS | 1 | |
| C202R162 |
| Chemokine receptor 4-like | 2.3 | 1.9 | NS | 1 | |
| C162R124 |
| C-X-C chemokine receptor type 1 | −5.3 | NS | 2.5 | 2 | |
| C159R1122 |
| Leukocyte cell-derived chemotaxin-2 paralog a | −8.2 | NS | 2.4 | 2 | |
| C133R130 |
| C-X-C motif chemokine 11-like | −4.4 | NS | 2.0 | 2 | |
| C183R0282 |
| C-X-C motif chemokine 2 (MIP2) paralog b | NS | NS | 3.1 | 2 | |
| C230R100 |
| Interleukin-1 beta | NS | NS | 2.2 | 2 | |
| C197R010 |
| Interleukin 11 | NS | NS | 3.7 | 2 | |
|
| C070R1625 |
| Complement factor H | −2.9 | −2.8 | NS | 3, 1 |
| C195R1223 |
| CD59 glycoprotein | −2.9 | −2.4 | NS | 1 | |
| C232R0832 |
| Complement C4 | −3.0 | −2.2 | NS | 1 | |
| C184R062 |
| Complement factor D | NS | −2.2 | NS | 4 | |
| C153R129 |
| C3a anaphylatoxin chemotactic receptor | −2.6 | −2.2 | NS | 1 | |
| C073R0142 |
| C5a anaphylatoxin chemotactic receptor 1 | −1.7 | NS | NS | 3 | |
| C191R156 |
| Complement factor B | 2.2 | 2.1 | NS | 1 | |
|
| C089R005 |
| Coagulation factor III (tissue factor) | −3.9 | −2.3 | NS | 1 |
|
| C009R0783 |
| Tissue factor pathway inhibitor 2 precursor | −3.3 | −2.8 | NS | 1 |
| C013R163 |
| Coagulation factor X | 2.1 | 1.7 | NS | 1 | |
| C137R1373 |
| Coagulation factor V | NS | NS | 2.5 | 2 | |
| C127R168 |
| Plasminogen activator inhibitor 1 | −5.5 | NS | 2.3 | 2 | |
|
| C145R001 |
| C-reactive protein | −2.2 | −2.6 | NS | 1 |
|
| C068R1542 |
| Midkine | −2.3 | −1.8 | NS | 1 |
|
| C254R103 |
| Prostaglandin E synthase | −2.0 | −1.7 | NS | 1 |
| C042R0873 |
| Vascular cell adhesion protein 1 | −2.4 | −1.6 | NS | 1 | |
| C003R128 |
| Prostaglandin D2 receptor 2 | 2.3 | NS | NS | 3 | |
|
| C139R032 |
| Radical S-adenosyl methionine domain-containing protein 2 (Viperin) paralog a | −2.3 | −2.7 | NS | 1 |
| C080R0313 |
| Interferon-induced protein 44 (p44) (Microtubule-associated protein 44) | −1.8 | −2.3 | NS | 1,4 | |
| C055R128 |
| Interferon-induced protein with tetratricopeptide repeats 5 | −2.3 | −2.3 | NS | 1 | |
| C218R011 |
| Interferon a3 paralog a | 2.2 | 2.3 | NS | 1 | |
| C168R125 |
| E3 ubiquitin-protein ligase TRIM8 | −1.8 | −1.8 | NS | 1 | |
| C184R150 |
| Zinc-binding protein A33 | −2.4 | −2.1 | NS | 1 | |
|
| C024R014 |
| Putative defense protein Hdd11 | −24.9 | −24.6 | NS | 1 |
|
| C164R1253 |
| CD99 antigen-like protein 2 | −2.4 | −2.7 | NS | 1 |
| C029R1162 |
| CD83 antigen paralog a | −1.7 | −1.7 | NS | 1 | |
| C200R158 |
| Complement C1q tumor necrosis factor-related protein 6 | −2.3 | −2.5 | NS | 1 | |
| C230R128 |
| Lipopolysaccharide-binding protein (LBP) | −1.9 | −1.9 | NS | 1 | |
| C092R0997 |
| Lipopolysaccharide-induced tumor necrosis factor-alpha | −1.7 | −1.8 | NS | 1 | |
| C107R1233 |
| Complement component 1 Q subcomponent-binding protein, mitochondrial | −1.9 | NS | NS | 3 | |
| C121R047 |
| Tumor necrosis factor receptor superfamily member 11B | NS | −2.1 | NS | 4 | |
| C076R108 |
| Fibrinogen-like protein 1 | −3.9 | −2.4 | NS | 1 | |
| C234R046 |
| Cathelicidin antimicrobial peptide paralog a | NS | 2.9 | 4.0 | 2 | |
| C222R090 |
| Cathelicidin antimicrobial peptide paralog b | −2.7 | NS | 2.9 | 2 | |
| C098R103 |
| Fibroblast growth factor 1 | −11.8 | NS | 5.0 | 2 | |
| C138R013 |
| Arginase-2 | NS | NS | 1.9 | 2 | |
| C249R1332 |
| Complement C1q-like protein 2 | NS | 10.3 | NS | 4 | |
| C234R0425 |
| NLR family CARD domain-containing protein 3 | 1.7 | 2.2 | NS | 3, 1 | |
| C095R050 |
| Complement C1q tumor necrosis factor-related protein 3 | 4.1 | 12.0 | NS | 1, 4 | |
|
| C243R111 |
| HLA (MHC) class I histocompatibility antigen, B-51 alpha chain | −2.3 | −2.6 | NS | 1 |
| C211R164 |
| HLA (MHC) class I histocompatibility antigen, alpha chain H | −3.7 | −3.8 | NS | 1 | |
| C141R11418 |
| Beta-2-microglobulin | −1.6 | −1.7 | NS | 1 | |
| C263R031 |
| Immunoglobulin lambda constant 3 | −3.2 | −3.8 | NS | 1 | |
| C250R1447 |
| High affinity immunoglobulin epsilon receptor subunit gamma | −1.7 | −1.7 | NS | 1 | |
| C229R1696 |
| Immunoglobulin mu chain C region | −5.0 | NS | NS | 3 | |
1−5 Refer to Table 1 for details on all column constructions.
Summary of details about the real-time quantitative polymerase chain reaction (QPCR)-analyzed genes of interest (GOIs) from different functional themes.
| Functional Theme 1 | Gene Description 2 | Gene Symbol_v1 3 | General Function 4 | Enriched GO Terms Associated 5 | Segment in MA 6 | Pathway Figure(s) |
|---|---|---|---|---|---|---|
| 1. ECM degradation, tissue repair/remodeling and wound healing | TIMP metalloproteinase inhibitor 2 |
| Modulating the activity of several MMPs | Activation of MMPs, Degradation of the ECM | 2 |
|
| collagenase 3-like/matrix metalloproteinase-13 |
| ECM catabolism, cartilage degradation, tissue remodeling, wound healing | Activation of MMPs, Degradation of the ECM, Collagen degradation/catabolic process | 2 | ||
| matrix metalloproteinase 2 (72 kDa type IV collagenase) |
| ECM catabolism, tissue repair/remodeling, inflammation | Extracellular space, ECM organization, Degradation of the ECM | 1 | ||
| matrix metalloproteinase-23 |
| ECM catabolism | Extracellular space, ECM organization, Collagen-containing ECM | 1 | ||
| matrix metalloproteinase-20 # |
| ECM catabolism | Not identified by SAM | - | - | |
| matrix metalloproteinase-19 |
| ECM catabolism | Extracellular space, ECM organization, Degradation of the ECM | 1 | ||
| matrix metalloproteinase-9 |
| ECM catabolism, leukocyte migration | Activation of MMPs, Degradation of the ECM, Collagen degradation/catabolic process, Regulation of inflammatory response | 2, 3 | ||
| fibronectin |
| ECM assembly, cell motility, adhesion, wound healing | Extracellular space, ECM organization, Acute-phase response | 1, 2 | ||
| biglycan-like |
| Collagen fiber assembly, ECM organization, matrix mineralization | Extracellular space, ECM organization, Collagen-containing ECM | 1 | ||
| 2. Immunity and defense (Not including antiviral response) | cathelicidin |
| Antibacterial activity | Defense response to bacterium, Antimicrobial humoral immune response mediated by antimicrobial peptide | 2 |
|
| beta-galactoside-binding lectin |
| Regulating apoptosis, cell proliferation and cell differentiation | Extracellular space, Regulation of immune system process | 1 | ||
| CD59 glycoprotein |
| Complement MAC inhibition | Regulation of immune system process, Cell surface receptor signaling pathway | 1 | ||
| CD83 |
| Antigen presentation and lymphocyte activation | Regulation of immune system process, Leukocyte activation, Positive regulation of immune system process | 1 | ||
| complement C1q tumor necrosis factor-related protein 3 |
| Regulatory role in immune system | $ Negative regulation of inflammatory response, Positive regulation of cytokine secretion, Immune system process | 1 | ||
| complement C1q-like protein 2 |
| Regulate excitatory synapses | $ Extracellular region, Immune system process | 4 |
| |
| C-reactive protein |
| Inflammation, acute phase response, defense | Leukocyte mediated immunity, Regulation of immune system process, Defense response | 1 | ||
| coagulation factor V-like |
| Central regulator of hemostasis | Platelet alpha granule lumen, Platelet degranulation | 2 |
| |
| putative defense protein Hdd11 |
| Putative antimicrobial activity | $ Defense response to other organism, Response to stimulus, Innate immune response | 1 | ||
| CCAAT/enhancer-binding protein beta-like |
| Transcription factor for immune and inflammatory genes | Defense response to bacterium, Regulation of cytokine biosynthetic process, Acute-phase response | 2 |
| |
| 3. Chemotaxis and signaling | C-X-C motif chemokine 2/MIP2-aplha/permeability factor 2-like |
| Hematoregulatory chemokine | Myeloid leukocyte migration, Neutrophil chemotaxis, Chemokine-mediated signaling pathway | 2 |
|
| leukocyte cell derived chemotaxin 2 |
| Chemotactic activity, chondrocyte proliferation | $ Response to stimulus, Immune system process | 2 |
| |
| C-C motif chemokine 17-like |
| T-lymphocytes trafficking and activation | Response to cytokine, Cellular response to cytokine stimulus | 3 | ||
| chemokine receptor 4-like |
| Regulator of chemotaxis | $ Response to stimulus, Immune system process | 1 | ||
| C-X-C motif chemokine 11-like |
| Chemotactic for activated T-cells, neutrophils or monocytes | Myeloid leukocyte migration, Neutrophil chemotaxis, Chemokine-mediated signaling pathway | 2 |
| |
| 4. Antiviral response | radical S-adenosyl methionine domain-containing protein 2, alias (viperin) |
| Antiviral | Immune system, Regulation of immune system process | 1 | |
| interferon a3 |
| Antiviral | Immune system process, Response to stimulus | 1 | ||
| 5. Antioxidant activity and redox homeostasis | thioredoxin |
| Redox homeostasis | $ Antioxidant activity, Response to oxygen levels, Response to stress | 2, 3 | |
| glutathione S-transferase A |
| Redox homeostasis | $ Response to stress/chemical | 1 | ||
| glutathione peroxidase 7 |
| Redox homeostasis | $ Antioxidant activity, Response to stimulus | 1 | ||
| redox-regulatory protein fam213a (peroxiredoxin-like 2A) |
| Redox homeostasis | $ Antioxidant activity, Regulation of immune system process | 1 | ||
| peroxiredoxin 1 |
| Redox homeostasis | $ Removal of superoxide radicals, Response to oxidative stress | 3 | ||
| neutrophil cytosol factor 2-like isoform X2 |
| NADPH oxidase, redox homeostasis | $ Superoxide-generating NADPH oxidase activator activity, Respiratory burst | 1 |
1 Based on functional classes, candidate genes are categorized under five themes for discussion purposes. 2 Name(s) or alias(es) obtained from annotation. Refer the Supplementary File S1 for additional details. 3 Official gene symbols (version 1) are based on multiple annotations and the majority of them are represented in HUGO Gene Nomenclature Committee (HGNC) (https://www.genenames.org/) and/or GeneCards (https://www.genecards.org/) databases. 4 General overview of the function of each candidate gene extracted from the UniProtKB database (https://www.uniprot.org/uniprot/). 5 Selected enriched GO terms associated with a GOI obtained from enrichment analyses. Additional details are available in Supplementary files. 6 In which segment (refer to Figure 2) of the microarray data list, the majority of the DEPs representing this transcript is present. # This was not identified by the microarray in this study. * Putative gene symbol of ifna (LOC106607463). $ One or more terms were obtained from UniProtKB/Blast2GO analyses.
Figure 7Correlation between the microarray and real-time quantitative polymerase chain reaction (QPCR) data, and QPCR confirmation of selected microarray-identified genes in theme 1 (Table 1 and Table 3) associated with ECM, tissue repair, and wound healing. (A) Scatterplot of log2-transformed gene expression fold-changes (FC) between treatment groups calculated from the microarray log2 ratios and log2-transformed QPCR relative quantity (RQ) ratios for all the QPCR-assayed transcripts. Each dot represents either an ADJ versus PRE, ATT versus PRE, or ATT versus ADJ comparison (i.e., one biological replicate) for a given target transcript. (B–O) Boxplots of QPCR data for the abundance of selected transcripts associated with ECM degradation, tissue repair/remodeling, and wound healing. Plots reveal median RQ values and interquartile ranges. Different letters above bars represent significant differences between groups (one-way analysis of variance (ANOVA), Tukey’s post hoc test, p < 0.05). Inset table below each plot shows FC of GOI from microarray and QPCR. Numbers with negative sign represent fold downregulation calculated as the inverse of FC (i.e., −1/FC) for the values less than one. When more than one probe represents a transcript in the microarray, the average FC is shown in the inset table. Numbers of probes contributing to the average FC are provided in Table 1 and Table 2. Bold letters indicate that a FC is statistically significant in QPCR or microarray by ANOVA and modified t-test, respectively. NS, found non-significant in the microarray. Refer to the heatmaps for each theme provided in Supplementary Figure S7. MA, microarray.
Figure 8QPCR confirmation of selected microarray-identified transcripts in theme 2 (Table 2 and Table 3) that are primarily associated with immunity and defense (not including antiviral response). For details of the captions, refer to Figure 7.
Figure 9QPCR confirmation of selected microarray-identified transcripts in themes 3 and 4 (Table 2 and Table 3). Transcript abundance of selected transcripts associated with chemotaxis and signaling (theme 3), and antiviral response (theme 4). For details of the captions, please refer to Figure 7, (*cxcl2 (alias mip2, macrophage inflammatory protein 2) also demonstrates homology with cxcl8/interleukin 8 (il8)).
Figure 10QPCR confirmation of selected microarray-identified transcripts in theme 5 (Table 1 and Table 3) that are associated with antioxidant activity and redox homeostasis. For details of the captions, refer to Figure 7.
Figure 11Principal coordinate analysis (PCoA) and correlation analysis of fin transcript expression data from QPCR with phenotypic factors. Standardized and log2-transformed data, respectively, were used in PCoA and correlation analyses. (A) Similarities and dissimilarities among treatment groups revealed by PCoA performed by PRIMER 6.1.15. (B) log2-transformed data were subjected to factor analysis using IBM SPSS Statistics (v25). Matrix represents the Pearson correlation coefficients between 8 phenotypic factors (columns; e.g., chalimus count) and both fin gene expression and the phenotypic factors (rows). Positive and negative correlations are indicated with green and red, respectively. A number for the corresponding correlation is displayed if the correlation is significant (p < 0.05). TCC, total chalimus count; W, weight; L, length; HSI, hepatosomatic index (HSI = 100×(liver weight/W)); SSI, spleen-somatic index (SSI = 1000× (spleen weight/W)); VSI, viscerosomatic index (VSI = 100× (viscera weight/W)), and K, Fulton’s condition factor (K = 100× (W/L3)).
Figure 12Overview of infection trial, sampling, and microarray design. (A) The design of the sea lice infection experiment. Sampling points and corresponding developmental stages of lice are indicated along the timeline (dpi, days post-infection). (B) Schematic sketch of fin sampling (not drawn to scale). Pelvic fin tips were sampled from chalimus-attachment (ATT) and adjacent (ADJ) sites. (C) Common reference-based microarray experimental design. Arrows represent the biological replicates used from three treatment groups (PRE, fins from control fish prior to lice exposure (n = 6); ATT and ADJ, fins from chalimus-attachment and adjacent sites, respectively, both sampled from same fish (n = 6)). The base and arrowhead show the Cy3-labelled reference pool and Cy5-labelled experimental samples, respectively.